Corixa Sells Bexxar Rights To GSK As Part Of Restructuring
This article was originally published in The Pink Sheet Daily
Executive Summary
The cost-cutting effort includes the elimination of 160 positions at the company's South San Francisco and Seattle operations, Corixa says. Copromotion partner GlaxoSmithKline will take over Bexxar development and marketing responsibilities effective Dec. 31.
You may also be interested in...
GSK Acquisition Of Corixa Means End To Royalty Payments
GSK agrees to pay $300 mil. for Corixa in an M&A play to pick up the biotech's adjuvant technology. The deal will allow GSK to avoid paying adjuvant therapy royalty payments. Corixa's technology is used in GSK's high-profile Cervarix HPV vaccine.
GSK Acquisition Of Corixa Means End To Royalty Payments
GSK agrees to pay $300 mil. for Corixa in an M&A play to pick up the biotech's adjuvant technology. The deal will allow GSK to avoid paying adjuvant therapy royalty payments. Corixa's technology is used in GSK's high-profile Cervarix HPV vaccine.
GSK Bexxar No Longer Rituxan Dependent For Non-Hodgkin's Lymphoma
The company will promote Bexxar as a "true second-line therapy" in patients who have relapsed after any regimen containing Rituxan and/or chemotherapy. Previously, patients had to be refractory to rituximab prior to considering Bexxar as a therapeutic option.